LearnGlossaryMarketStocksSuperinvestorsSign in

DAWN

Day One Biopharmaceuticals, Inc.

Healthcare · $2.2B market cap

Verdict

We can't put a fair value on DAWN right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-3.3% a year✗
Sales growth20.6% a year✓
Free cash flow growth—?
Return on invested capital-43.4%✗

Follow DAWN

Track it on your watchlist and see the full analysis. Free.

Create a free account

About Day One Biopharmaceuticals, Inc.

Operating as a clinical-stage biopharmaceutical entity, Day One Biopharmaceuticals, Inc. is dedicated to discovering and commercializing precise therapeutic options for individuals battling genetically defined cancers. A key asset is DAY101, an orally administered, brain-permeable type II pan-rapidly accelerated fibrosarcoma kinase inhibitor, currently undergoing Phase II clinical trials for young patients…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Apr 24, 2026. How the Payback Price works